Advanced search
Publication Cover
Modern Rheumatology Volume 26, 2016 - Issue 4
Journal homepage
2,666
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial

Yoshiya TanakaThe First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Correspondence[email protected]
,
Masayoshi HarigaiDepartment of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan,
,
Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan,
,
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan,
,
Naoki IshiguroDepartment of Orthopedic Surgery, Graduate School & Faculty of Medicine, Nagoya University, Nagoya, Japan,
,
Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,
,
Nobuyuki MiyasakaDepartment of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan,
,
Takao KoikeNTT Sapporo Medical Center and Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan,
,
Daniel BakerJanssen Research & Development, LLC, Spring House, PA, USA,
,
Yutaka IshiiJanssen Pharmaceutical K.K., Tokyo, Japan, and
,
Toru YoshinariDevelopment Planning and Coordination Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
& the GO-FORTH study group show all
Pages 481-490 | Received 20 Jul 2015, Accepted 13 Oct 2015, Published online: 23 Dec 2015

Figures & data

Figure 1. Patient disposition through 156 weeks. AE, adverse event.

Figure 1. Patient disposition through 156 weeks. AE, adverse event.

Figure 2. The proportions of patients* with an ACR20 (A), ACR50 (B), and ACR70 (C) response through week 156. *Observed data without imputation. ACR20/50/70, ≥ 20%/50%/70% improvement in American College of Rheumatology criteria; MTX, methotrexate.

Figure 2. The proportions of patients* with an ACR20 (A), ACR50 (B), and ACR70 (C) response through week 156. *Observed data without imputation. ACR20/50/70, ≥ 20%/50%/70% improvement in American College of Rheumatology criteria; MTX, methotrexate.

Figure 3. The proportions of patients* with remission as defined by the CDAI (A), SDAI (B), and Boolean (C) criteria through week 156. *Observed data without imputation. CDAI, clinical disease activity index; MTX, methotrexate; SDAI, simplified disease activity index.

Figure 3. The proportions of patients* with remission as defined by the CDAI (A), SDAI (B), and Boolean (C) criteria through week 156. *Observed data without imputation. CDAI, clinical disease activity index; MTX, methotrexate; SDAI, simplified disease activity index.

Table 1. Clinical efficacy results at weeks 52, 104, and 156.

Table 2. Radiographic results through 156 weeks.

Table 3. Adverse events through 156 weeks.

Supplemental material

1109762_Supplemental_Table_1.pdf

Download PDF (79.2 KB)

Related Research Data

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
Source: Figshare
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
Source: Figshare
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.